Ge Long Hui·2025-08-02 17:41Core Viewpoint - The collaboration between Borui Pharmaceutical and China Resources Sanjiu focuses on the development, registration, production, and commercialization of BGM0504 injection in mainland China, with Borui retaining full ownership of the product while granting exclusive development and commercialization rights to Sanjiu [1][2]. Group 1: Collaboration Details - Borui grants Sanjiu exclusive cooperation development and commercialization licenses while retaining full ownership of the product [1]. - Sanjiu will pay up to 282 million yuan in milestone payments for the development of BGM0504, along with additional sales milestone payments [1]. - Borui will only pay a service fee based on net sales after the product is launched, without transferring other rights [1]. Group 2: Market and Sales Implications - Sanjiu's leading OTC channel capabilities will help Borui enhance its sales performance, compensating for its own sales team limitations [2]. - The collaboration sets a precedent for paying development costs and sales milestones to obtain exclusive promotional rights, showcasing Sanjiu's commitment to supporting innovative pharmaceutical companies [2]. Group 3: Pipeline and Future Prospects - Borui has a rich pipeline in innovative drugs and complex generics, with BGM1812 in preclinical stages and BGM0504 tablets expected to enter clinical trials within the year [3]. - The company anticipates deepening cooperation with Sanjiu as new products, especially the oral BGM0504 tablets, are launched, leveraging Sanjiu's promotional capabilities to maximize domestic sales [3]. - BGM0504 injection has nearly completed bridging clinical trials in the U.S., indicating potential for international market entry [3]. Group 4: Financial Forecast - The company maintains its profit forecast, expecting net profits of 260 million, 300 million, and 430 million yuan for 2025-2027, corresponding to P/E ratios of 160, 139, and 97 times [3].